The strong Phase 2 data supports SPY001 as a best-in-class anti-α4β7 candidate, with potential for accelerated development. Traders should monitor upcoming data readouts for SPY002 (mid-2026) and SPY003 (Q3 2026), as well as enrollment trends in combination arms, which could further de-risk the pipeline and attract partnership interest.
Price Chart
Executive Summary
Spyre Therapeutics announced positive 12-week induction data from Part A of its Phase 2 SKYLINE trial, showing SPY001 achieved a statistically significant 9.2-point reduction in RHI score (p<0.0001) with strong secondary outcomes and a favorable safety profile. Enrollment has closed for Part A and moved to Part B, which includes monotherapy and combination cohorts, with data readouts expected through 2026–2027.
Key Facts
- SPY001 met primary endpoint with 9.2-point reduction in RHI score (p<0.0001) at Week 12 in Phase 2 SKYLINE trial Part A.
- Secondary endpoints: 40% clinical remission rate and 51% endoscopic improvement rate.
- SPY001 was well tolerated with no drug-related serious adverse events; most common AE was back pain (n=2).
- Part B of the SKYLINE trial is now enrolling, including combination cohorts with SPY002 and SPY003.
- Proof-of-concept data for SPY002 expected mid-2026, SPY003 in Q3 2026, and full Part B data in 2027.
Financial Impact
Potential blockbuster profile for SPY001 in ulcerative colitis, with best-in-class positioning and combination potential driving valuation upside.
Risk Factors
- Future data may not confirm current results, especially in randomized, placebo-controlled Part B.
- Regulatory disagreement with trial design or endpoints could delay approval path.
- Competition from existing anti-integrin and anti-cytokine therapies in IBD space.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3272353 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 28d ago | Insider Cluster | $88.98 $90.80 | ▼ −2.05% | ▼ −3.25% | $93.19 (−4.73%) |
Aug 11, 2026 7w ago | Insider Cluster | $102.74 $107.82 | ▼ −4.94% | ▼ −5.35% | $93.19 (+9.30%) |
Aug 6, 2026 8w ago | Insider Cluster | $103.42 $101.85 | ▲ +1.52% | ▲ +2.73% | $93.19 (+9.89%) |
Jul 3, 2026 13w ago | Insider Cluster | $86.63 $98.75 | ▲ +13.99% | ▲ +13.06% | $93.19 (+7.57%) |
Jun 27, 2026 13w ago | Insider Cluster | $90.16 $88.74 | ▲ +1.57% | ▲ +2.96% | $93.19 (−3.36%) |
Jun 26, 2026 14w ago | S-3ASR | $90.16 $88.74 | ▼ −1.57% | ▼ −2.96% | $93.19 (+3.36%) |
Jun 24, 2026 14w ago | Insider Cluster | $86.24 $88.89 | ▼ −3.07% | ▼ −1.37% | $93.19 (−8.06%) |
Jun 15, 2026 15w ago | 8-K | $83.58 $100.32 | ▲ +20.03% | ▲ +21.41% | $93.19 (+11.50%) |
Jun 12, 2026 16w ago | Institutional Cluster | $80.79 $88.34 | ▲ +9.35% | ▲ +8.67% | $93.19 (+15.35%) |
Jun 11, 2026 16w ago | Institutional Cluster | $80.77 $87.49 | ▲ +8.32% | ▲ +7.89% | $93.19 (+15.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access